- Home
- KELYA vs URGN Comparison
KELYA vs URGN Comparison
Compare KELYA & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KELYA
- URGN
- Stock Information
- Founded
- KELYA 1946
- URGN 2004
- Country
- KELYA United States
- URGN United States
- Employees
- KELYA N/A
- URGN N/A
- Industry
- KELYA Professional Services
- URGN Biotechnology: Pharmaceutical Preparations
- Sector
- KELYA Consumer Discretionary
- URGN Health Care
- Exchange
- KELYA Nasdaq
- URGN Nasdaq
- Market Cap
- KELYA 403.0M
- URGN 463.2M
- IPO Year
- KELYA N/A
- URGN 2017
- Fundamental
- Price
- KELYA $12.38
- URGN $10.34
- Analyst Decision
- KELYA Buy
- URGN Strong Buy
- Analyst Count
- KELYA 1
- URGN 7
- Target Price
- KELYA $25.00
- URGN $36.75
- AVG Volume (30 Days)
- KELYA 249.3K
- URGN 662.5K
- Earning Date
- KELYA 05-08-2025
- URGN 05-12-2025
- Dividend Yield
- KELYA 2.46%
- URGN N/A
- EPS Growth
- KELYA N/A
- URGN N/A
- EPS
- KELYA N/A
- URGN N/A
- Revenue
- KELYA $4,451,600,000.00
- URGN $90,398,000.00
- Revenue This Year
- KELYA $9.54
- URGN $36.82
- Revenue Next Year
- KELYA $3.92
- URGN $119.10
- P/E Ratio
- KELYA N/A
- URGN N/A
- Revenue Growth
- KELYA N/A
- URGN 9.29
- 52 Week Low
- KELYA $10.80
- URGN $8.94
- 52 Week High
- KELYA $23.85
- URGN $20.70
- Technical
- Relative Strength Index (RSI)
- KELYA 61.41
- URGN 50.33
- Support Level
- KELYA $10.92
- URGN $9.63
- Resistance Level
- KELYA $11.80
- URGN $11.75
- Average True Range (ATR)
- KELYA 0.40
- URGN 0.79
- MACD
- KELYA 0.18
- URGN -0.00
- Stochastic Oscillator
- KELYA 97.59
- URGN 43.36
About KELYA Kelly Services Inc.
Kelly Services Inc is a provider of workforce solutions and consulting, and staffing services. The company's operations are divided into four business segments, namely Professional & Industrial, Science, Education, Outsourcing & Consulting Group, and International. Other than OCG, each segment delivers talent through staffing services, permanent placement, or outcome-based services. OCG segment delivers talent solutions, including managed service providers, payroll process outsourcing, recruitment process outsourcing, and talent advisory services. International also delivers RPO talent solutions within its local markets. The majority of revenue is derived from Professional & Industrial.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.